Matthew Collin1, Paul Milne. 1. Human Dendritic Cell Laboratory, Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle upon Tyne, UK.
Abstract
PURPOSE OF REVIEW: This article summarizes recent research on the ontogeny of Langerhans cells and regulation of their homeostasis in quiescent and inflamed conditions. RECENT FINDINGS: Langerhans cells originate prenatally and may endure throughout life, independently of bone marrow-derived precursors. Fate-mapping experiments have recently resolved the relative contribution of primitive yolk sac and fetal liver hematopoiesis to the initial formation of Langerhans cells. In postnatal life, local self-renewal restores Langerhans cell numbers following chronic or low-grade inflammatory insults. However, severe inflammation recruits de-novo bone marrow-derived precursors in two waves; a transient population of classical monocytes followed by uncharacterized myeloid precursors that form a stable self-renewing Langerhans cell network as inflammation subsides. Human CD1c⁺ dendritic cells have Langerhans cell potential in vitro, raising the possibility that dendritic cell progenitors provide the second wave. Langerhans cell development depends upon transforming growth factor beta receptor signaling with distinct pathways active during differentiation and homeostasis. Langerhans cell survival is mediated by multiple pathways including mechanistic target of rapamycin and extracellular signal-regulated kinase signaling, mechanisms that become highly relevant in Langerhans cell neoplasia. SUMMARY: The study of Langerhans cells continues to provide novel and unexpected insights into the origin and regulation of myeloid cell populations. The melding of macrophage and dendritic cell biology, shaped by a unique habitat, is a special feature of Langerhans cells.
PURPOSE OF REVIEW: This article summarizes recent research on the ontogeny of Langerhans cells and regulation of their homeostasis in quiescent and inflamed conditions. RECENT FINDINGS: Langerhans cells originate prenatally and may endure throughout life, independently of bone marrow-derived precursors. Fate-mapping experiments have recently resolved the relative contribution of primitive yolk sac and fetal liver hematopoiesis to the initial formation of Langerhans cells. In postnatal life, local self-renewal restores Langerhans cell numbers following chronic or low-grade inflammatory insults. However, severe inflammation recruits de-novo bone marrow-derived precursors in two waves; a transient population of classical monocytes followed by uncharacterized myeloid precursors that form a stable self-renewing Langerhans cell network as inflammation subsides. HumanCD1c⁺ dendritic cells have Langerhans cell potential in vitro, raising the possibility that dendritic cell progenitors provide the second wave. Langerhans cell development depends upon transforming growth factor beta receptor signaling with distinct pathways active during differentiation and homeostasis. Langerhans cell survival is mediated by multiple pathways including mechanistic target of rapamycin and extracellular signal-regulated kinase signaling, mechanisms that become highly relevant in Langerhans cell neoplasia. SUMMARY: The study of Langerhans cells continues to provide novel and unexpected insights into the origin and regulation of myeloid cell populations. The melding of macrophage and dendritic cell biology, shaped by a unique habitat, is a special feature of Langerhans cells.
Authors: Yaming Wang; Kristy J Szretter; William Vermi; Susan Gilfillan; Cristina Rossini; Marina Cella; Alexander D Barrow; Michael S Diamond; Marco Colonna Journal: Nat Immunol Date: 2012-06-24 Impact factor: 25.606
Authors: Caroline Hutter; Max Kauer; Ingrid Simonitsch-Klupp; Gunhild Jug; Raphaela Schwentner; Judith Leitner; Peter Bock; Peter Steinberger; Wolfgang Bauer; Nadia Carlesso; Milen Minkov; Helmut Gadner; Georg Stingl; Heinrich Kovar; Ernst Kriehuber Journal: Blood Date: 2012-10-16 Impact factor: 22.113
Authors: Kristin Seré; Jea-Hyun Baek; Julia Ober-Blöbaum; Gerhard Müller-Newen; Frank Tacke; Yoshifumi Yokota; Martin Zenke; Thomas Hieronymus Journal: Immunity Date: 2012-11-16 Impact factor: 31.745
Authors: Nighat Yasmin; Sabine Konradi; Gregor Eisenwort; Yvonne M Schichl; Maria Seyerl; Thomas Bauer; Johannes Stöckl; Herbert Strobl Journal: J Invest Dermatol Date: 2013-01-10 Impact factor: 8.551
Authors: Thomas Bauer; Anna Zagórska; Jennifer Jurkin; Nighat Yasmin; René Köffel; Susanne Richter; Bernhard Gesslbauer; Greg Lemke; Herbert Strobl Journal: J Exp Med Date: 2012-10-15 Impact factor: 14.307
Authors: Clément Ghigo; Isabelle Mondor; Audrey Jorquera; Jonathan Nowak; Stephan Wienert; Sonja P Zahner; Björn E Clausen; Hervé Luche; Bernard Malissen; Frederick Klauschen; Marc Bajénoff Journal: J Exp Med Date: 2013-08-12 Impact factor: 14.307
Authors: Nighat Yasmin; Thomas Bauer; Madhura Modak; Karin Wagner; Christopher Schuster; Rene Köffel; Maria Seyerl; Johannes Stöckl; Adelheid Elbe-Bürger; Daniel Graf; Herbert Strobl Journal: J Exp Med Date: 2013-11-04 Impact factor: 14.307
Authors: Amel Sengal; Jessica Velazquez; Meryl Hahne; Thomas M Burke; Harshal Abhyankar; Robert Reyes; Walter Olea; Brooks Scull; Olive S Eckstein; Camille Bigenwald; Catherine M Bollard; Wendong Yu; Miriam Merad; Kenneth L McClain; Carl E Allen; Rikhia Chakraborty Journal: Blood Date: 2021-04-01 Impact factor: 25.476
Authors: Dieke van Dinther; Dorian A Stolk; Rieneke van de Ven; Yvette van Kooyk; Tanja D de Gruijl; Joke M M den Haan Journal: J Leukoc Biol Date: 2017-07-20 Impact factor: 4.962